Kidney cancer study reveals Real-World use of top drug combos
NCT ID NCT06345183
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at 327 adults with advanced kidney cancer who received one of two drug combinations (nivolumab+ipilimumab or pembrolizumab+lenvatinib) in real-world U.S. clinics. Researchers collected data on patient characteristics, treatment patterns, and outcomes from medical records. The goal was to describe how these approved therapies are actually used outside of clinical trials, not to test new treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
327 people
The number who actually took part.
- Started
-
Feb 2024
- Finished
-
Apr 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult participants diagnosed with advanced Renal Cell Carcinoma (aRCC) who received Nivolumab+Ipilimumab or Pembrolizumab+Lenvatinib combination therapy in the first line (1L) setting
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18 years and older with diagnosis of Advanced Renal Cell Carcinoma (aRCC) with predominantly clear-cell histology 2. Received any of the following therapies in the first-line setting: 1. Nivolumab + Ipilimumab between 8/1/2021 and 6 months prior to data collection 2. Pembrolizumab + Lenvatinib between 8/1/2021and 6 months prior to data collection 3. Participant had at least 6 months of follow-up from initiation of index treatment (patients who deceased prior to 6 months since index treatment initiation would still be eligible) Exclusion Criteria: 1. Receipt of any immunotherapy or tyrosine kinase inhibitor (TKI) therapy as part of a Randomized Controlled Trial (RCT) 2. Participant received any systemic therapy for Advanced Renal Cell Carcinoma (aRCC) prior to index therapy, including neoadjuvant or adjuvant therapy 3. Any active malignancy in the 3 years prior to initiation of 1L therapy for aRCC, except for locally curable cancers that have been cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix, or breast cancer, or localized prostate cancer with a Gleason score ≤3+4 that has been treated more than 12 months prior to full study screening and considered to have a very low risk of recurrence.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced renal cell carcinoma (ARCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cardinal Health
Dublin, Ohio, 43017, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.